Frazier Life Sciences Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $2.36 Billion
- Q3 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 9,874,511 shares of ARQT stock, worth $247 Million. This represents 7.87% of its overall portfolio holdings.
Number of Shares
9,874,511
Previous 9,874,511
-0.0%
Holding current value
$247 Million
Previous $138 Million
34.45%
% of portfolio
7.87%
Previous 7.3%
Shares
5 transactions
Others Institutions Holding ARQT
# of Institutions
253Shares Held
127MCall Options Held
404KPut Options Held
133K-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$179 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...